HEADER SUGAR BINDING PROTEIN 04-APR-14 4Q1P TITLE GALECTIN-1 IN COMPLEX WITH LIGAND NB169 COMPND MOL_ID: 1; COMPND 2 MOLECULE: GALECTIN-1; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: GAL-1, 14 KDA LAMININ-BINDING PROTEIN, HLBP14, 14 KDA COMPND 5 LECTIN, BETA-GALACTOSIDE-BINDING LECTIN L-14-I, GALAPTIN, HBL, HPL, COMPND 6 LACTOSE-BINDING LECTIN 1, LECTIN GALACTOSIDE-BINDING SOLUBLE 1, COMPND 7 PUTATIVE MAPK-ACTIVATING PROTEIN PM12, S-LAC LECTIN 1; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LGALS1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS RATIONAL DRUG DESIGN, SUGAR BINDING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR C.GRIMM,N.BERTLEFF-ZIESCHANG REVDAT 1 07-OCT-15 4Q1P 0 JRNL AUTH C.GRIMM,N.BERTLEFF-ZIESCHANG JRNL TITL GALECTIN-1 IN COMPLEX WITH LIGAND NB169 JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 1.46 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.8.2_1309) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE- REMARK 3 : KUNSTLEVE,LI-WEI HUNG,ROBERT IMMORMINO, REMARK 3 : TOM IOERGER,AIRLIE MCCOY,ERIK MCKEE,NIGEL REMARK 3 : MORIARTY,REETAL PAI,RANDY READ,JANE REMARK 3 : RICHARDSON,DAVID RICHARDSON,TOD ROMO,JIM REMARK 3 : SACCHETTINI,NICHOLAS SAUTER,JACOB SMITH, REMARK 3 : LAURENT STORONI,TOM TERWILLIGER,PETER REMARK 3 : ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.46 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 40.32 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 3 NUMBER OF REFLECTIONS : 49185 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.151 REMARK 3 R VALUE (WORKING SET) : 0.149 REMARK 3 FREE R VALUE : 0.188 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.070 REMARK 3 FREE R VALUE TEST SET COUNT : 2492 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 40.3311 - 3.8253 0.98 2774 143 0.1541 0.1715 REMARK 3 2 3.8253 - 3.0365 0.99 2675 141 0.1381 0.1531 REMARK 3 3 3.0365 - 2.6528 0.99 2645 110 0.1447 0.1801 REMARK 3 4 2.6528 - 2.4103 0.99 2620 139 0.1387 0.1646 REMARK 3 5 2.4103 - 2.2375 0.99 2599 170 0.1274 0.1661 REMARK 3 6 2.2375 - 2.1056 1.00 2640 119 0.1253 0.1390 REMARK 3 7 2.1056 - 2.0002 1.00 2594 150 0.1220 0.1944 REMARK 3 8 2.0002 - 1.9131 0.98 2554 132 0.1316 0.1744 REMARK 3 9 1.9131 - 1.8395 1.00 2600 131 0.1394 0.1941 REMARK 3 10 1.8395 - 1.7760 1.00 2578 140 0.1569 0.2394 REMARK 3 11 1.7760 - 1.7205 1.00 2580 146 0.1661 0.2311 REMARK 3 12 1.7205 - 1.6713 0.99 2550 162 0.1698 0.2303 REMARK 3 13 1.6713 - 1.6273 0.99 2583 137 0.1785 0.2602 REMARK 3 14 1.6273 - 1.5876 0.99 2550 143 0.1759 0.2626 REMARK 3 15 1.5876 - 1.5515 0.98 2508 141 0.1910 0.2680 REMARK 3 16 1.5515 - 1.5185 0.98 2564 126 0.2228 0.3006 REMARK 3 17 1.5185 - 1.4881 0.99 2529 133 0.2520 0.3924 REMARK 3 18 1.4881 - 1.4600 0.99 2550 129 0.2720 0.3352 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.10 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.180 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 20.410 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.013 2345 REMARK 3 ANGLE : 1.537 3194 REMARK 3 CHIRALITY : 0.080 350 REMARK 3 PLANARITY : 0.007 423 REMARK 3 DIHEDRAL : 19.018 889 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 4Q1P COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-APR-14. REMARK 100 THE RCSB ID CODE IS RCSB085493. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : SI(111) REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M-F REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 49191 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.460 REMARK 200 RESOLUTION RANGE LOW (A) : 55.533 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 13.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.06700 REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.46 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 47.33 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.34 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.5 M AMMONIUM SULFATE, PH 7.5, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 289K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 21.63350 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 55.53300 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 29.18650 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 55.53300 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 21.63350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 29.18650 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -1 REMARK 465 MET A 0 REMARK 465 ALA A 1 REMARK 465 GLY B -1 REMARK 465 MET B 0 REMARK 465 ALA B 1 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 C LYS B 129 H CME B 130 1.36 REMARK 500 C VAL A 87 H CME A 88 1.38 REMARK 500 C LYS A 129 H CME A 130 1.38 REMARK 500 HE22 GLN B 93 O HOH B 388 1.52 REMARK 500 O PHE B 126 O HOH B 396 1.92 REMARK 500 O HOH B 402 O HOH B 415 1.94 REMARK 500 O HOH B 406 O HOH B 413 1.98 REMARK 500 OE1 GLN B 93 O HOH B 395 2.03 REMARK 500 O HOH B 361 O HOH B 397 2.05 REMARK 500 O HOH A 381 O HOH A 383 2.07 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 369 O HOH B 379 4455 1.95 REMARK 500 O HOH A 399 O HOH B 419 4455 2.13 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 134 CB - CG - OD1 ANGL. DEV. = 6.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 50 87.05 -154.48 REMARK 500 PRO A 78 47.29 -88.98 REMARK 500 PRO B 78 51.12 -93.60 REMARK 500 ASP B 125 48.10 -90.22 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2XT A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BME A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2XT B 202 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 4Q1R RELATED DB: PDB REMARK 900 RELATED ID: 4Q26 RELATED DB: PDB REMARK 900 RELATED ID: 4Q27 RELATED DB: PDB REMARK 900 RELATED ID: 4Q2F RELATED DB: PDB DBREF 4Q1P A 0 134 UNP P09382 LEG1_HUMAN 1 135 DBREF 4Q1P B 0 134 UNP P09382 LEG1_HUMAN 1 135 SEQADV 4Q1P GLY A -1 UNP P09382 EXPRESSION TAG SEQADV 4Q1P GLY B -1 UNP P09382 EXPRESSION TAG SEQRES 1 A 136 GLY MET ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU SEQRES 2 A 136 LYS PRO GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA SEQRES 3 A 136 PRO ASP ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SEQRES 4 A 136 SER ASN ASN LEU CYS LEU HIS PHE ASN PRO ARG PHE ASN SEQRES 5 A 136 ALA HIS GLY ASP ALA ASN THR ILE VAL CYS ASN SER LYS SEQRES 6 A 136 ASP GLY GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL SEQRES 7 A 136 PHE PRO PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE SEQRES 8 A 136 THR PHE ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP SEQRES 9 A 136 GLY TYR GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU SEQRES 10 A 136 ALA ILE ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE SEQRES 11 A 136 LYS CME VAL ALA PHE ASP SEQRES 1 B 136 GLY MET ALA CYS GLY LEU VAL ALA SER ASN LEU ASN LEU SEQRES 2 B 136 LYS PRO GLY GLU CME LEU ARG VAL ARG GLY GLU VAL ALA SEQRES 3 B 136 PRO ASP ALA LYS SER PHE VAL LEU ASN LEU GLY LYS ASP SEQRES 4 B 136 SER ASN ASN LEU CYS LEU HIS PHE ASN PRO ARG PHE ASN SEQRES 5 B 136 ALA HIS GLY ASP ALA ASN THR ILE VAL CYS ASN SER LYS SEQRES 6 B 136 ASP GLY GLY ALA TRP GLY THR GLU GLN ARG GLU ALA VAL SEQRES 7 B 136 PHE PRO PHE GLN PRO GLY SER VAL ALA GLU VAL CME ILE SEQRES 8 B 136 THR PHE ASP GLN ALA ASN LEU THR VAL LYS LEU PRO ASP SEQRES 9 B 136 GLY TYR GLU PHE LYS PHE PRO ASN ARG LEU ASN LEU GLU SEQRES 10 B 136 ALA ILE ASN TYR MET ALA ALA ASP GLY ASP PHE LYS ILE SEQRES 11 B 136 LYS CME VAL ALA PHE ASP MODRES 4Q1P CME A 16 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1P CME A 88 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1P CME A 130 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1P CME B 16 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1P CME B 88 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 4Q1P CME B 130 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 16 19 HET CME A 88 19 HET CME A 130 19 HET CME B 16 19 HET CME B 88 19 HET CME B 130 19 HET 2XT A 201 42 HET BME A 202 8 HET SO4 B 201 5 HET 2XT B 202 42 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM 2XT PROPYL 2-(ACETYLAMINO)-4-O-{3-O-[(1-BENZYL-1H-1,2,3- HETNAM 2 2XT TRIAZOL-4-YL)METHYL]-BETA-D-GALACTOPYRANOSYL}-2-DEOXY- HETNAM 3 2XT BETA-D-GLUCOPYRANOSIDE HETNAM BME BETA-MERCAPTOETHANOL HETNAM SO4 SULFATE ION FORMUL 1 CME 6(C5 H11 N O3 S2) FORMUL 3 2XT 2(C27 H40 N4 O11) FORMUL 4 BME C2 H6 O S FORMUL 5 SO4 O4 S 2- FORMUL 7 HOH *224(H2 O) HELIX 1 1 PRO B 101 GLY B 103 5 3 SHEET 1 A12 ALA A 67 TRP A 68 0 SHEET 2 A12 ASP A 54 ASP A 64 -1 N ASP A 64 O ALA A 67 SHEET 3 A12 ASN A 40 ALA A 51 -1 N ARG A 48 O THR A 57 SHEET 4 A12 PHE A 30 ASP A 37 -1 N LEU A 32 O PHE A 45 SHEET 5 A12 TYR A 119 GLY A 124 -1 O ASP A 123 N VAL A 31 SHEET 6 A12 VAL A 5 SER A 7 -1 N ALA A 6 O MET A 120 SHEET 7 A12 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 A12 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 A12 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 A12 ASN B 40 ALA B 51 -1 O PHE B 45 N LEU B 32 SHEET 11 A12 ASP B 54 ASP B 64 -1 O ASN B 61 N HIS B 44 SHEET 12 A12 ALA B 67 TRP B 68 -1 O ALA B 67 N ASP B 64 SHEET 1 B12 GLN A 72 ARG A 73 0 SHEET 2 B12 ASP A 54 ASP A 64 -1 N CYS A 60 O GLN A 72 SHEET 3 B12 ASN A 40 ALA A 51 -1 N ARG A 48 O THR A 57 SHEET 4 B12 PHE A 30 ASP A 37 -1 N LEU A 32 O PHE A 45 SHEET 5 B12 TYR A 119 GLY A 124 -1 O ASP A 123 N VAL A 31 SHEET 6 B12 VAL A 5 SER A 7 -1 N ALA A 6 O MET A 120 SHEET 7 B12 VAL B 5 LEU B 11 -1 O VAL B 5 N SER A 7 SHEET 8 B12 ILE B 117 GLY B 124 -1 O MET B 120 N ALA B 6 SHEET 9 B12 PHE B 30 ASP B 37 -1 N ASN B 33 O ALA B 121 SHEET 10 B12 ASN B 40 ALA B 51 -1 O PHE B 45 N LEU B 32 SHEET 11 B12 ASP B 54 ASP B 64 -1 O ASN B 61 N HIS B 44 SHEET 12 B12 GLN B 72 ARG B 73 -1 O GLN B 72 N CYS B 60 SHEET 1 C10 GLU A 105 PRO A 109 0 SHEET 2 C10 ASN A 95 LYS A 99 -1 N LEU A 96 O PHE A 108 SHEET 3 C10 SER A 83 PHE A 91 -1 N THR A 90 O THR A 97 SHEET 4 C10 LEU A 17 VAL A 23 -1 N VAL A 23 O SER A 83 SHEET 5 C10 PHE A 126 PHE A 133 -1 O LYS A 129 N ARG A 20 SHEET 6 C10 PHE B 126 ASP B 134 -1 O PHE B 133 N LYS A 129 SHEET 7 C10 CME B 16 VAL B 23 -1 N GLU B 22 O LYS B 127 SHEET 8 C10 SER B 83 PHE B 91 -1 O SER B 83 N VAL B 23 SHEET 9 C10 ASN B 95 LYS B 99 -1 O LYS B 99 N CME B 88 SHEET 10 C10 GLU B 105 PRO B 109 -1 O PHE B 108 N LEU B 96 LINK C GLU A 15 N CME A 16 1555 1555 1.33 LINK C CME A 16 N LEU A 17 1555 1555 1.33 LINK C CME A 88 N ILE A 89 1555 1555 1.33 LINK C CME A 130 N AVAL A 131 1555 1555 1.33 LINK C CME A 130 N BVAL A 131 1555 1555 1.33 LINK C GLU B 15 N CME B 16 1555 1555 1.33 LINK C CME B 16 N LEU B 17 1555 1555 1.31 LINK C VAL B 87 N CME B 88 1555 1555 1.32 LINK C CME B 88 N ILE B 89 1555 1555 1.31 LINK C CME B 130 N AVAL B 131 1555 1555 1.33 LINK C CME B 130 N BVAL B 131 1555 1555 1.33 LINK C VAL A 87 N CME A 88 1555 1555 1.32 LINK C LYS A 129 N CME A 130 1555 1555 1.32 LINK C LYS B 129 N CME B 130 1555 1555 1.32 SITE 1 AC1 16 SER A 29 VAL A 31 HIS A 44 ASN A 46 SITE 2 AC1 16 ARG A 48 HIS A 52 ASN A 61 GLU A 71 SITE 3 AC1 16 ARG A 73 GLY A 124 HOH A 319 HOH A 349 SITE 4 AC1 16 HOH A 367 HOH A 373 HOH A 375 THR B 70 SITE 1 AC2 7 LYS A 36 LEU A 114 GLU A 115 ALA A 116 SITE 2 AC2 7 HOH A 311 HOH A 374 LYS B 28 SITE 1 AC3 9 PRO A 101 ASP A 102 HOH A 330 HOH A 365 SITE 2 AC3 9 ASN B 10 LYS B 12 HOH B 347 HOH B 355 SITE 3 AC3 9 HOH B 381 SITE 1 AC4 17 GLN A 72 HOH A 359 HOH A 362 SER B 29 SITE 2 AC4 17 HIS B 44 ASN B 46 ARG B 48 HIS B 52 SITE 3 AC4 17 ASN B 61 GLU B 71 ARG B 73 ASP B 123 SITE 4 AC4 17 GLY B 124 HOH B 312 HOH B 374 HOH B 377 SITE 5 AC4 17 HOH B 391 CRYST1 43.267 58.373 111.066 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.023112 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017131 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009004 0.00000